Alliance for Pandemic Preparedness

June 8, 2021

Long-COVID Following Mild SARS CoV-2 Infection Characteristic T Cell Alterations and Response to Antihistamines

Category:

Topic:

Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] “Long COVID” patients with persistent symptoms (mean symptom duration 269 days) treated with histamine receptor antagonists (HRA) (n=25) reported an average reduction in symptom burden by 60%. 20% reported complete symptom resolution, 52% experienced some improvement, and 6 reported no change with a mean time to response of 30 days. By contrast, the 67% of untreated cohort (n=24) reported no change and 8% developed new additional symptoms. Long COVID patients had distinct T-cell profiles compared with 16 controls who recovered from COVID-19 but did not have long COVID, including reduced CD4+ and CD8+ effector memory cells. However, T-cell profiles did not predict responses to HRA.

Glynne et al. (June 7, 2021). Long-COVID Following Mild SARS CoV-2 Infection Characteristic T Cell Alterations and Response to Antihistamines. Pre-print downloaded Jun 8 from https://doi.org/10.1101/2021.06.06.21258272